WallStSmart

Health In Tech, Inc. Class A Common Stock (HIT)vsVuzix Corp Cmn Stk (VUZI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Health In Tech, Inc. Class A Common Stock generates 460% more annual revenue ($34.08M vs $6.09M). VUZI leads profitability with a 0.0% profit margin vs -2.4%. HIT earns a higher WallStSmart Score of 29/100 (F).

HIT

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.29

VUZI

Avoid

16

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: -11.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HIT.

VUZIUndervalued (+40.5%)

Margin of Safety

+40.5%

Fair Value

$4.15

Current Price

$4.23

$0.08 discount

UndervaluedFair: $4.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HIT2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.2910/10

Safe zone — low bankruptcy risk

VUZI1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

HIT4 concerns · Avg: 2.5/10
Market CapQuality
$64.69M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-3.7%2/10

ROE of -3.7% — below average capital efficiency

Free Cash FlowQuality
$-3.68M2/10

Negative free cash flow — burning cash

VUZI4 concerns · Avg: 3.5/10
Price/BookValuation
14.1x4/10

Trading at 14.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$259.45M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : HIT

The strongest argument for HIT centers on Debt/Equity, Altman Z-Score.

Bull Case : VUZI

The strongest argument for VUZI centers on Debt/Equity.

Bear Case : HIT

The primary concerns for HIT are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : VUZI

The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

HIT profiles as a turnaround stock while VUZI is a value play — different risk/reward profiles.

HIT is growing revenue faster at 9.4% — sustainability is the question.

HIT generates stronger free cash flow (-4M), providing more financial flexibility.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HIT scores higher overall (29/100 vs 16/100). VUZI offers better value entry with a 40.5% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Health In Tech, Inc. Class A Common Stock

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Health In Tech, Inc. (HIT) is a leading innovator in the digital health sector, specializing in technology solutions that enhance healthcare delivery and patient outcomes. Utilizing advanced data analytics and proprietary software, HIT enables healthcare providers and patients to make informed decisions, thereby increasing operational efficiencies. The company’s strong commitment to compliance and cybersecurity positions it favorably within the rapidly growing digital health landscape. As the market continues to evolve, HIT is strategically positioned for growth, aiming to be a pivotal player in the global advancement of technology-driven healthcare solutions.

Vuzix Corp Cmn Stk

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.

Want to dig deeper into these stocks?